Duration of peginterferon therapy in acute hepatitis C: A randomized trial

Kamal, S.M., Moustafa, K.N., Chen, J., Fehr, J., Moneim, A.A., Khalifa, Khalifa, El Gohary, L.A., Ramy, A.H., Madwar, M.A., Rasenack, J., Afdhal, N.H.,

Abstract


Spontaneous resolution of acute hepatitis C virus infection cannot be predicted, and chronic evolution of the disease occurs in a majority of cases. To assess the efficacy and safety of peginterferon alpha-2b administered for 8, 12, or 24 weeks in patients with acute hepatitis C virus infection a total of 161 patients were identified with acute hepatitis C virus infection. Of these, 30 patients refused treatment but were retained in the study as a nonrandomized comparison group. Of the 131 patients who consented to treatment, 29 patients spontaneously resolved, leaving 102 patients randomly assigned to peginterferon alpha-2b (1.5 microg/kg) for 8 weeks (group A; n=34), 12 weeks (group B; n=34), and 24 weeks (group C; n=34). The primary end point was sustained virologic response. An intent-to-treat analysis was used for efficacy and safety end points. Sustained virologic response was achieved in 23/34 (67.6%), 28/34 (82.4%), and 31/34 (91.2%) of patients in groups A, B, and C, respectively; all had undetectable hepatitis C virus RNA 48 weeks after the end of therapy. Treatment for 8 or 12 weeks was effective in genotypes 2, 3, and 4, whereas genotype 1 required 24 weeks of therapy. The 8- and 12-week regimens were associated with fewer adverse events compared with the 24-week regimen. In conclusion, peginterferon alpha-2b effectively induces high sustained virologic response rates in patients with acute hepatitis C virus infection, thus preventing development of chronic hepatitis C. Duration of treatment should be further optimized based on genotype and rapid virologic response at week 4.


Other data

Title Duration of peginterferon therapy in acute hepatitis C: A randomized trial
Authors Kamal, S.M. ; Moustafa, K.N. ; Chen, J. ; Fehr, J. ; Moneim, A.A. ; Khalifa, Khalifa ; El Gohary, L.A. ; Ramy, A.H. ; Madwar, M.A. ; Rasenack, J. ; Afdhal, N.H. 
Issue Date 2006
Journal Hepatology 
DOI 5
923-31
http://www.scopus.com/inward/record.url?eid=2-s2.0-33646562220&partnerID=MN8TOARS
43
10.1002/hep.21197
PubMed ID 16628640
Scopus ID 2-s2.0-33646562220

Recommend this item

Similar Items from Core Recommender Database

Google ScholarTM

Check

Citations 29 in pubmed
Citations 120 in scopus
views 56 in Shams Scholar


Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.